Table 1.
Selected Ongoing Trials in BCBLM Diagnostic Imaging (November 2023).
| NCT Identifier | Official Title | Sponsor | Study Population | N | Status | Intervention | Outcome Measures | Results |
|---|---|---|---|---|---|---|---|---|
| NCT06072807 | Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer | Weill Medical College of Cornell University | Patients with ER+ BCBM planned for radiation treatment | est: 20 | not yet recruiting | 18F- FES PET/CT scan in addition to standard imaging | Proportion of cases in which there is change in management based on FES PET/CT imaging | pending |
| NCT04246879 | Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases | Duke University | Patients with brain metastases and signs of radiographic progression after stereotactic radiosurgery | est: 37 | recruiting | Delayed MRI Contrast Enhancement | Detection of true tumor by delayed MRI as determined by surgical biopsy | pending |
| NCT05054998 | A Pilot Study of Dual Time Point FDG PET MR Imaging Optimization for the Evaluation of Brain Metastasis | M.D. Anderson Cancer Center | Patients with brain metastases and plan for surgery or radiation, any solid organ metastases with at least 3 intraaxial and at least one enhancing >10 mm | est: 20 | recruiting | FDG-PET/MRI | Optimal imaging time after radiotracer administration to maximize discrimination between lesions and healthy parenchyma | pending |
| NCT05911230 | Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases- AiD GLIO Pilot Trial | University Hospital, Basel, Switzerland | Patients with GBM or Brain metastases with suspected progression on standard MRI after first-line therapy and plan for surgical resection | est: 10 | recruiting | ADW-MRI | Correlation between histopathology of resected tissue biopsy and tissue features from ADW-MRI | pending |
| NCT04111588 | Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases | Norwegian University of Science and Technology | Patients with glioma or brain metastasis with planned surgery/SRS | est: 160 | recruiting | Amino acid PET/MRI (18F-FACBC, 18F-FET, 11C-MET) | Differentiation of low and high-grade tumors at baseline, discrimination of recurrence vs. treatment-related changes | pending |
| NCT04244019 | Differentiating Radionecrosis From Tumour Progression Using Hybrid FLT-PET/MRI in Patients With Brain Metastases Treated With Stereotactic Radiosurgery. | University Health Network, Toronto | Paitients with previously treated brain metastasis and new intracranial lesion suspicious for progression, undergoing planned resection | est: 30 | recruiting | Hybrid FLT-PET/MRI | Differentiating radionecrosis from tumor; correlating with biopsy | pending |
| NCT05376878 | Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan | City of Hope Medical Center | Patients with HER2+ BCBM, eligible with LMC | est: 10 | recruiting | 64Cu-DOTA-trastuzumab PET/MRI | Quantification of 64Cu-DOTA-trastuzumab uptake, comparison of SUVmax values in responders vs. non-responders, progression-free survival | pending |
| NCT04689048 | Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery | Baptist Health South Florida | Patients with brain metastases with plan for SRS and at least one untreated lesion >2 cm | est: 20 | recruiting | 18 fluciclovine with PET/CT, MRI | Differences in sensitivity with 18F-fluciclovine enhancement in PET/CT and MRI, change in SUV parameters | pending |
| NCT03331601 | Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients | Universitair Ziekenhuis Brussel | Patients with BCBM, at least 1 lesion at least 8 mm diameter | est: 30 | recruiting | 68GaNOTA-Anti-HER2 VHH1 enhanced PET/CT | Tumor targeting potential using SUV values, change in uptake during or after treatment | pending |
| NCT05095766 | Differentiation Between Radionecrosis and Tumor Recurrence for Post-stereotactic Radiosurgery Follow-up by Pharmacokinetic Analyses in Perfusion MRI and Positron Emission Tomography | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Patients with brain metastasis having unergone gamma knife radiosurgery and presenting for first MRI folow-up | 40 | active | DCE-MRI, FET PET | Differentiate radionecrosis from tumor recurrence with DCE-MRI, FET PET or combination imaging | pending |
| NCT04752267 | Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain Tumors | University of Southern California | Patients with primary brain tumor or metastatic tumors with documented radiation therapy | 10 | active | 18F-FMAU PET/CT | Correlation between multiparametric MRI radiomics and dynamic 18F-FAMU PET to valuate tumors | pending |
| NCT00103038 | NCI-Sponsored Multi-Disciplinary Study for MR Imaging of Intravenous Superparamagnetic Crystalline Particle Ferumoxytol in Primary High-Grade Brain Tumors and/or Cerebral Metastases | OHSU Knight Cancer Institute | Patients with high grade glioma, CNS lymphoma or brain metastases | 155 | completed | 3T DCE-MRI with Ferumoxytol | Vascular Permeability (Ktrans), rCBV measurements, number and size of imaged metastases compared to gadolinium scans, overall survival | pending |
| NCT00938756 | Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer | Centre Oscar Lambret | Patients with breast cancer and LMC with or without BM, other malignancies with LMC included | est: 80 | unknown | CA 15-3 levels in CSF | Measured levels of CA 15-3 in CSF of patients with LMC | pending |
| NCT03068520 | Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease? | Assuta Medical Center | Patients with glial tumors or metastatic lesions treated with SRS | 140 | unknown | PET MR with 18F-DOPA | Distinguish between tumor and treatment related effects | pending |